Latest News

Frazer Goodwin joins FH Europe as Senior Policy Projects Manager on February 1st, 2022. In this newly created role, Frazer’s focus for the forthcoming period will be on the EU policy dimension to promote FH paediatric screening across the EU. As such he will be working very closely with the FH Europe’s member organizations to […]

“Homozygous familial hypercholesterolemia is a rare condition, extraordinarily difficult to treat, and without early identification and experienced care, leads to cardiac consequences early in life and often, death by age 30 years. New medications are on the horizon, but the prognosis remains grim. This paper shows that worldwide, much greater efforts are needed to help […]

In the January edition of FH Europe’s Heart Beat newsletter you’ll find the following: Information on our dedicated Policy Advisory Committee tasked with advocating for implementation of FH child screening across Europe. Insights on how we are working with people living with Lp(a) and medical experts to develop brochures and website content for patients. A […]

We are growing and need a superhero to help us deliver on our mission. The Virtual Office Manager and Executive Assistant plays a pivotal role in the day to day running of FH Europe’s team and wider voluntary structures of the charity.

Find the outcomes of the latest research on major adverse events caused by a rare and severe form of familial hypercholesterolaemia summarised for our community. A lay summary of “Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: a systematic review and meta-analysis”, published in European Journal of Preventive Cardiology has been prepared for FH Europe […]

In the December edition of FH Europe’s Heart Beat newsletter you’ll find the following: A special “End of Year” message from FH Europe’s Chair of the Board and Chief Executive. Information on how you can become a trustee of FH Europe, as we begin the search for new Patient Trustees. News of the renewed commitment […]
FH Europe is supported by an educational grant from Amgen Limited, Sanofi, Akcea Therapeutics Inc. and Amryt